In the article “An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion” by Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, Poitout V, Mancebo H, Mirmira RG, Gilchrist A, and Layden BT (Mol Endocrinol. 2015;29(7):1055–1066; doi: 10.1210/me.2015-1007), the data in Table 2 is identical to the calcium data presented in Table 3. However, as described in the manuscript, the values derived from these experiments are different. The correct Table 2 is reproduced below. The authors regret this error.
Table 2.
Potency and Efficacy of FFAR2 Agonists at Mouse FFAR2
| mFFAR2 | ||
|---|---|---|
| Calcium | ||
| Acetate | pEC50 | 2.32 ± 0.21 (n = 13) |
| pEmax | 2.27 ± 0.31 | |
| SCA14 | pEC50 | 7.80 ± 0.60 (n = 5) |
| pEmax | 3.19 ± 0.40 | |
| SCA15 | pEC50 | 5.44 ± 0.47 (n = 3) |
| pEmax | 2.01 ± 0.25 | |
| CMTB | pEC50 | NR (n = 4) |
| pEmax | ||
| CPTB | pEC50 | NR (n = 4) |
| pEmax |
pEC50 and pEmax values for each FFAR2 agonist in the calcium mobilization assays conducted in the βTC3 mouse β cell line is shown. NR refers to no response, where this indicates the absence of a calcium flux response to the agonist during a multiple concentration titration. Shown are mean ± SEM.